The Author(s) 2013. This article is published with open access at Springerlink.com Background Understanding the nature and time course of the pharmacodynamic effects of attention-deficit/hyper-activity disorder (ADHD) medications is useful. The Cognitive Drug Research Computerized Battery of Tests (CDR-CBT) is a 20-min battery of ten standardized, vali-dated neuropsychometric tasks. Objective This pilot study examined the sensitivity and responsiveness of the CDR-CBT for assessing cognitive function in adults with ADHD prior to and up to 16 h postdose during treatment with lisdexamfetamine dimesy-late (LDX) or mixed amphetamine salts immediate release (MAS-IR; various generics available). Methods This was a double-blind three-period crossov...
Journal Article;BACKGROUND The purpose of this multicenter Spanish study was to evaluate the respon...
Full list of author information is available at the end of the articleBackground Attention deficit h...
BACKGROUND: SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the tr...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction Ther...
Journal Article;Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for pa...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives A seco...
Background: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adu...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction: Lis...
Long-acting medications have been developed and approved for use in the treatment of attention-defic...
Context: Previous studies have reported hypofunc-tion, structural abnormalities, and biochemical abn...
The Author(s) 2015. This article is published with open access at Springerlink.com Background In cli...
Objective: To evaluate stimulant medication on symptoms and functioning for college students with AD...
Attention-deficit hyperactivity disorder (ADHD) is awell-established diagnosis in children. However,...
BackgroundLisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hype...
is a highly prevalent and impairing psychiatric disorder that affects both children and adults. Ther...
Journal Article;BACKGROUND The purpose of this multicenter Spanish study was to evaluate the respon...
Full list of author information is available at the end of the articleBackground Attention deficit h...
BACKGROUND: SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the tr...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction Ther...
Journal Article;Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for pa...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives A seco...
Background: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adu...
The Author(s) 2013. This article is published with open access at Springerlink.com Introduction: Lis...
Long-acting medications have been developed and approved for use in the treatment of attention-defic...
Context: Previous studies have reported hypofunc-tion, structural abnormalities, and biochemical abn...
The Author(s) 2015. This article is published with open access at Springerlink.com Background In cli...
Objective: To evaluate stimulant medication on symptoms and functioning for college students with AD...
Attention-deficit hyperactivity disorder (ADHD) is awell-established diagnosis in children. However,...
BackgroundLisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hype...
is a highly prevalent and impairing psychiatric disorder that affects both children and adults. Ther...
Journal Article;BACKGROUND The purpose of this multicenter Spanish study was to evaluate the respon...
Full list of author information is available at the end of the articleBackground Attention deficit h...
BACKGROUND: SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the tr...